Interestingly, treatment with a well‐known Akt inhibitor, MK2206, significantly reduced CHEK1 expression in CRC cells (Supplementary Figure S6G) by reducing the transcriptional activity of CHEK1 (Supplementary Figure S6H). Here, AKT1 is linked to colorectal carcinoma.